{
    "sigir-20141": {
        "NCT00149227": {
            "relevance_explanation": "The patient has hypertension, which is one of the target conditions in the KYOTO HEART Study. The study aims to assess the add-on effect of valsartan on morbidity and mortality in high-risk patients with hypertension. Given that the patient's symptoms started recently and are accompanied by other factors such as nausea and dyspnea, but not explicitly linked to hypertension or other target conditions of the study directly in the provided text. However, the presence of hypertension makes the patient potentially relevant to the study\u2019s objectives.",
            "relevance_score_R": 70.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for having a clinical diagnosis of hypertension and having one or more risk factors (obesity). The patient does not have any mentioned exclusion criteria such as previous administration of ARB, IHD within 6 months after PCI, severe/malignant/secondary hypertensive patients, pregnancy or childbearing potential, history of heart failure, unstable angina, myocardial infarction, PTCA or CABG within the preceding 6 months, arrhythmia needing treatment or accompanied by symptoms with second or third degree AV block, severe renal impairment (serum creatinine >3.0 mg/dl), or severe hepatic impairment. Thus, the patient appears to be eligible based on the provided information.",
            "eligibility_score_E": 70.0
        },
        "NCT01397994": {
            "relevance_explanation": "The patient presents with episodic pressing/burning anterior chest pain, which could be indicative of angina. However, the patient note does not explicitly mention chronic stable angina or provide details on the Exercise Myocardial Perfusion Spect Scan results. Despite this, the symptoms described could align with the target conditions of the clinical trial, making the patient potentially relevant. The patient's age, gender, and willingness to comply with the study procedures also align with the trial's inclusion criteria. Yet, the lack of specific information about the patient's condition being chronic stable angina and the absence of detailed diagnostic results (like the Exercise Myocardial Perfusion Spect Scan) directly related to the trial's primary inclusion criterion reduces the relevance score.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient is eligible based on gender (female) and age (58 years old) which fit within the 25 to 65 years range. The patient also understands and is willing to comply with all study procedures and restrictions. However, the patient's condition (episodic pressing/burning anterior chest pain) does not clearly meet the primary inclusion criterion of chronic stable angina with specific diagnostic evidence (abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes) as required by the trial. The patient's hypertension and absence of other exclusionary conditions (like valvular heart disease, cardiomyopathy, myocardial infarction in <6 months, unstable angina) do not exclude her but also do not fulfill all necessary inclusion criteria for the trial.",
            "eligibility_score_E": -10.0
        }
    },
    "sigir-20142": {
        "NCT00711399": {
            "relevance_explanation": "The patient presents with fever, dyspnea and cough for 2 days, which includes cough or shortness of breath. The clinical trial is focused on assessing cough and wheeze with a breath sound documenting device, making the patient's condition highly relevant to the trial. The patient's symptoms align with the target conditions of the trial (respiratory sounds) and the patient will provide informed consent and comply with the trial protocol.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets some inclusion criteria (cough or shortness of breath) and is not excluded by some exclusion criteria (no chest tubes and no skin lesions that would preclude attachment of sensors). However, the patient is in respiratory distress, which is an exclusion criterion. Despite providing informed consent and being able to comply with the trial protocol, the patient's respiratory distress excludes them from the trial.",
            "eligibility_score_E": -45.0
        },
        "NCT02618655": {
            "relevance_explanation": "The patient presents with fever, dyspnea and cough which are symptoms that could be related to tick-borne diseases. The clinical trial focuses on the diagnosis of tick-borne diseases in patients with unexplained acute fever. Given the patient's recent travel to Colorado and symptoms such as fever and cough, this trial seems relevant as it aims to diagnose tick-borne diseases which the patient might be at risk of having due to his travel history and symptoms.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient does not meet the inclusion criterion of having fever for more than one week. However\uff0c the patient's temperature is higher than 38\u2103 which meets one of the inclusion criteria. There is not enough information to confirm if full physical and laboratory examinations have been carried out after one week. The patient is not excluded based on the provided exclusion criteria as there is no indication that the fever is due to non-infectious diseases or that the patient left with automatic discharge.",
            "eligibility_score_E": -10.0
        }
    },
    "sigir-20143": {
        "NCT02490059": {
            "relevance_explanation": "The patient has a left lung mass on chest x-ray and a solitary mass in the right frontal lobe, which aligns with the clinical trial's target condition of lung cancer. The patient's symptoms of mild exertional dyspnea and occasional cough also suggest a potential connection to the trial's focus on solitary pulmonary nodules. Therefore, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having a pulmonary nodule as indicated by the chest x-ray and CT scan. The patient also provides informed consent and will comply with the trial protocol. However, there is not enough information to determine if the patient's nodule is non-visible on standard-size bronchoscopy. Despite this, the patient's eligibility is supported by the available information, making them a potential candidate for the trial.",
            "eligibility_score_E": 80.0
        },
        "NCT01452971": {
            "relevance_explanation": "The patient is a 58-year-old nonsmoker white female with a left lung mass on chest x-ray, which directly aligns with the clinical trial's target condition of lung cancer. The trial aims to study the interaction between tumor susceptibility gene glycine N-methyltransferase (GNMT) and lung cancer. Given the patient's diagnosis of a left lung mass and the absence of any information suggesting ineligibility due to age or other exclusion criteria, the patient is highly relevant to this clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being a lung cancer patient as evidenced by the left lung mass on chest x-ray. The patient is also above the age of 18, which is the only mentioned exclusion criterion related to age. There is no mention of the patient having any condition that would exclude them from participating in the trial based on the provided information. The patient has also agreed to provide informed consent and will comply with the trial protocol, indicating their willingness and ability to participate. Therefore, the patient appears to be eligible for the clinical trial.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-20144": {
        "NCT02390596": {
            "relevance_explanation": "The patient note describes a 2-year-old boy with symptoms consistent with Kawasaki disease, including high fever, irritability, conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy. These symptoms align with the American Heart Association definition for complete or incomplete Kawasaki disease. The clinical trial is specifically designed for patients with Kawasaki disease who failed to respond to standard treatment. Given the patient's presentation and the trial's focus on Kawasaki disease and the use of anakinra for patients who have not responded to standard therapy (e.g. intravenous immunoglobulins) the patient is highly relevant to this clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets several inclusion criteria for the clinical trial: the patient has Kawasaki disease according to the American Heart Association definition (fever \u2265 5 days and \u2265 4 of 5 main clinical signs) and the patient failed to respond to standard therapy of KD (as indicated by persistence or recrudescence of fever). The patient\u2019s weight can be inferred to be \u2265 5 kg given the age (2 years old). The patient will provide informed consent and comply with the trial protocol. However there is not enough information to fully determine eligibility regarding health insurance and agreement to have effective contraception. The patient is not excluded by any of the listed exclusion criteria based on the provided information.",
            "eligibility_score_E": 40.0
        },
        "NCT00841789": {
            "relevance_explanation": "The patient is a 2-year-old boy with symptoms consistent with Kawasaki Disease, including high fever, conjunctivitis, strawberry tongue, and cervical lymphadenopathy. The clinical trial is focused on Kawasaki Disease and the patient's condition matches the target condition of the trial. The patient's age is within the specified range for males (2 months to 20 years). The patient will provide informed consent through their parents and has symptoms consistent with Kawasaki Disease presentation. Therefore\u060c the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of having Kawasaki Disease presentation and providing informed consent. However\u060c the patient is excluded due to having active severe infections within 4 weeks before the screening visit and severe comorbidities such as desquamation of the skin of the fingers and toes. Despite meeting some criteria and not being excluded by others such as laboratory toxicity or specific thresholds for blood counts or other conditions like HIV-positive status or history of immunosuppressing diseases\u3001 the patient's eligibility is negatively impacted by the mentioned exclusion criteria.",
            "eligibility_score_E": -45.0
        }
    },
    "sigir-20145": {
        "NCT00163709": {
            "relevance_explanation": "The patient presents to the emergency department with shortness of breath, which is a key symptom targeted by the clinical trial. The trial aims to examine the effectiveness of a new heart failure blood test in improving outcomes for patients presenting with shortness of breath. Given the patient's symptoms and the trial's objectives, there is a clear relevance between the patient's condition and the trial's focus. The patient's age and presentation to the ED also align with the trial's inclusion criteria.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being over 40 years old and presenting to the ED with shortness of breath. The patient does not have a traumatic cause of dyspnea, which would have been an exclusion criterion. There is no mention of severe renal disease, cardiogenic shock, or plans for an early transfer to another hospital within 24 hours, which are additional exclusion criteria. Therefore, based on the provided information, the patient appears to be eligible for the trial.",
            "eligibility_score_E": 90.0
        },
        "NCT01935141": {
            "relevance_explanation": "The patient presents with symptoms such as shortness of breath and malaise, which could be indicative of pulmonary embolus, a condition that the clinical trial aims to detect. The patient's recent history of remaining in bed for two weeks and tenderness on the left upper thoracic wall and right calf, along with the elevated D-dimer, further supports the relevance of this trial to the patient's condition. The clinical trial's focus on detecting multiple pulmonary emboli using CT pulmonary angiography aligns with the patient's potential diagnosis, making this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "Although the patient is relevant to the trial due to the suspicion of pulmonary embolus, the patient's eligibility is affected by the presence of congestive heart failure inferred from symptoms like shortness of breath and malaise. This condition aligns with exclusion criterion 0 (Class 3 or 4 Congestive Heart Failure), which excludes the patient from participating in the trial. Other exclusion criteria such as supraventricular tachycardia, history of contrast allergy, inability to give informed consent, and serum creatinine levels >1.28 mg/dl do not appear to directly exclude the patient based on the provided information. However, the patient's congestive heart failure status is a significant factor that affects eligibility.",
            "eligibility_score_E": -90.0
        }
    },
    "sigir-20146": {
        "NCT00015626": {
            "relevance_explanation": "The patient is relevant to the clinical trial because she has diabetes mellitus and is obese, which are both target conditions of the trial. The trial aims to prevent the complications of insulin resistance, including type-2 diabetes. The patient's painful skin lesion could be a complication of insulin resistance. Therefore\uff0c the patient's conditions align with the trial's objectives.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is eligible based on some criteria: she is obese and has a potential complication of insulin resistance (the painful skin lesion). However\u060c she is excluded due to her history of poor compliance with physician's recommendations regarding her diabetes medication and exercise. Despite this exclusion criterion being met\u060c other criteria such as the ability to give informed consent and not being critically ill are in her favor. Given the mix of met and unmet criteria and the specific exclusion due to non-compliance\u060c the eligibility score reflects a balance between these factors.",
            "eligibility_score_E": -45.0
        },
        "NCT02512159": {
            "relevance_explanation": "The patient is relevant to the clinical trial because she has a painful skin lesion on the left lower leg, which is consistent with the target conditions of the trial (foot ulcer and varicose ulcer). Additionally, her diagnosis of diabetes mellitus and persistently elevated HbA1c aligns with the trial's focus on patients with diabetes mellitus. The patient's reluctance to see a nutritionist and non-compliance with her diabetes medication or exercise does not directly impact her relevance to the trial. However, her willingness to provide informed consent and comply with the trial protocol is a positive factor for her relevance.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is eligible for the clinical trial because she meets several inclusion criteria: she has cutaneous leg ulcers due to diabetes mellitus (inclusion criterion 0), she is female (inclusion criterion 1), she is over 18 years (inclusion criterion 2), and she has comorbidities associated with diabetes mellitus (inclusion criterion 4). Although there is limited information about her basic laboratory results at admission (inclusion criterion 3), it does not explicitly exclude her. The patient is not excluded by any of the exclusion criteria: she is hemodynamically stable (exclusion criterion 0), there is no mention of septic shock (exclusion criterion 1), her skin lesion does not have exposed bone or tendon (exclusion criterion 2), and there is no mention of secondary cutaneous ulcer enteral fistula (exclusion criterion 3), cutaneous ulcer or cancer tumors (exclusion criterion 4), or cutaneous ulcer necrosis (exclusion criterion 6). However, the patient's skin lesion is oozing, which may be considered as active bleeding (exclusion criterion 5), but this is not clear. The patient's willingness to provide informed consent and comply with the trial protocol (exclusion criterion 9) supports her eligibility.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-20147": {
        "NCT01863628": {
            "relevance_explanation": "The patient is a 26-year-old obese woman with a history of bipolar disorder, which is the target condition of the clinical trial. The trial focuses on the prodromal stage of bipolar disorder and early intervention. The patient's current struggles with weight and eating have caused feelings of depression, difficulty sleeping, excessive anxiety and agitation. These symptoms align with the prodromal depressive symptoms and hypomania/mania symptoms mentioned in the trial. The patient's history of bipolar disorder and current symptoms make this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets some inclusion criteria such as having a biological parent diagnosed with bipolar disorder (not explicitly mentioned but implied through her own diagnosis) and exhibiting symptoms that could be part of the prodromal stage of bipolar disorder (e.g., depressive symptoms, anxiety). However, the patient is currently taking lithium carbonate and zolpidem, which are antipsychotic drugs, making her ineligible according to exclusion criterion 3. Despite this, the patient's condition and symptoms suggest a strong relevance to the trial's objectives.",
            "eligibility_score_E": -45.0
        },
        "NCT00845988": {
            "relevance_explanation": "The patient has bipolar disorder, which is a target condition of the clinical trial. The trial focuses on metabolic effects of switching to aripiprazole in patients with bipolar disorders. Given the patient's history of bipolar disorder and current struggles with weight and eating due to her medications (lithium carbonate and zolpidem) as mentioned in sentences <0.> and <1.>, this trial seems highly relevant to her situation. The patient's age (26 years old) also falls within the trial's inclusion criteria. Thus, the patient's condition and situation align with the trial's objectives and criteria.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets several inclusion criteria for the trial: she has bipolar disorder (criterion 0), is within the required age range (criterion 1), and has the decisional capacity to provide informed consent (criterion 2). However, there is insufficient information to confirm whether she has exhibited a clinically significant increase in body weight (>7% weight gain) after starting her current antipsychotic medications (criterion 3). The patient is not excluded based on the provided criteria regarding eating disorders, substance abuse, psychotic disorders (exclusion criterion 0), neurological and medical illnesses (exclusion criterion 1), or being pregnant/breast feeding (exclusion criterion 2). Given the information available, the patient seems to align with many of the trial's inclusion criteria but lacks specific details on weight gain since starting her medication.",
            "eligibility_score_E": 40.0
        }
    },
    "sigir-20148": {
        "NCT01519271": {
            "relevance_explanation": "The patient is experiencing symptoms of progressive memory loss and jerking movements of the lower extremities, which aligns with the clinical trial's target condition of Mild Cognitive Impairment in Parkinson's Disease. Although the patient note does not explicitly mention Parkinson's disease, the symptoms described are consistent with the condition. The neurologic examination confirms severe cognitive deficits and memory dysfunction, and the electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. These findings suggest that the patient's condition is relevant to the clinical trial's focus on mild cognitive impairment in Parkinson's disease.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient meets some of the inclusion criteria for the clinical trial. The patient is experiencing symptoms of mild cognitive impairment as determined by the neurologic examination and neuroimaging studies. Additionally, the patient is capable of giving informed consent as stated in the patient note. However, there is not enough information to determine if the patient meets all the inclusion criteria, such as being on a stable medication regimen for 2 months prior to starting the study. The patient's weight is also not mentioned, which is an exclusion criterion. Furthermore, there is no mention of Deep Brain Stimulation surgery or active suicide ideation, which are exclusion criteria. The patient's diagnosis of severe cognitive deficits and memory dysfunction could be indicative of dementia, but it is not explicitly stated. Given the available information, the patient appears to be partially eligible for the clinical trial but lacks sufficient detail to confirm full eligibility.",
            "eligibility_score_E": 40.0
        },
        "NCT01628315": {
            "relevance_explanation": "The patient's condition, which includes progressive memory loss and jerking movements of the lower extremities with severe cognitive deficits and memory dysfunction confirmed by neurologic examination and electroencephalogram showing generalized periodic sharp waves and neuroimaging studies showing moderately advanced cerebral atrophy does not directly align with the target conditions of the clinical trial which focuses on Multiple Sclerosis and Relapsing-remitting. However the patient's symptoms and diagnostic findings could be considered relevant in a broader context of neurodegenerative diseases and the impact of lesions on disease progression. Yet given the specific focus of the trial on Multiple Sclerosis and the lack of direct mention of the patient's condition in relation to this disease the relevance is not as high as it could be for a trial directly studying the patient's condition.",
            "relevance_score_R": 20.0,
            "eligibility_explanation": "The patient does not meet the inclusion criterion of being enrolled in the 2-year double-blind placebo-controlled ASA study and entering the 3-year extension study as there is no mention of such enrollment in the patient note. Furthermore there is insufficient information regarding the performance of MRI using a 1.5 T magnet and the collection of all 5 MRI time points which are necessary for the trial. The patient's eligibility is thus significantly impacted by these missing criteria and the inability to confirm other crucial aspects such as the processing of MRI images and the absence of exclusion criteria.",
            "eligibility_score_E": -20.0
        }
    },
    "sigir-20149": {
        "NCT01950026": {
            "relevance_explanation": "The patient's condition of having lesions on her neck does not directly relate to the clinical trial's focus on temperature skin changes after cryotherapy application. However, the trial's aim to reheat the skin in different ethnic groups could imply a broader interest in skin reactions, which might tangentially include lesion responses. Given the indirect connection and lack of explicit exclusion based on the provided information, the patient has some relevance to the trial.",
            "relevance_score_R": 20.0,
            "eligibility_explanation": "The patient's eligibility is uncertain due to lack of information about her ethnicity and health status regarding skin sensitivity or infectious diseases. However, based on the provided criterion-level eligibility predictions, the patient does not seem to be excluded by any known exclusion criteria. Her ability to provide informed consent and comply with the trial protocol is a positive factor but does not directly address the eligibility criteria.",
            "eligibility_score_E": 0.0
        },
        "NCT02615912": {
            "relevance_explanation": "The patient has visible skin lesions which could be related to dermatitis, making this trial somewhat relevant. However, the trial focuses on the dynamics of skin microflora following exposure to surfactants and the patient's condition may not be directly related to this. The patient's willingness to provide informed consent and comply with the trial protocol is a positive aspect.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient has visible skin disease (lesions on her neck) which directly corresponds to an exclusion criterion. Although the patient is willing to participate and comply with the protocol, the presence of visible skin disease excludes her from the trial. There is also insufficient information about the patient's Fitzpatrick Skin Type to confirm eligibility based on inclusion criteria.",
            "eligibility_score_E": -40.0
        }
    },
    "sigir-201410": {
        "NCT02097186": {
            "relevance_explanation": "The patient is 67 years old and has undergone cardiac catheterization via the right femoral artery, which led to a cool right foot and a pulsatile mass in her right groin. These conditions are related to the target conditions of the clinical trial (Abdominal Aortic Aneurysm and Critical Lower Limb Ischaemia). The patient's symptoms and medical history make this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets some inclusion criteria: she is older than 18 years and willing to give informed consent. However, there is not enough information to confirm if she is undergoing elective carotid endarterectomy or open abdominal aortic aneurysm repair. Additionally, the patient's estimated pre-operative glomerular filtration rate is not mentioned. The patient does not have any exclusion criteria mentioned in the patient note.",
            "eligibility_score_E": 40.0
        },
        "NCT02264964": {
            "relevance_explanation": "The patient underwent cardiac catheterization via the right femoral artery, which indicates a potential relevance to the clinical trial focused on catheterization in patients with hemodialysis. However, the patient note does not explicitly mention chronic renal failure requiring hemodialysis as the primary condition. The relevance is inferred from the context of catheterization and the patient's compliance with the trial protocol. Given the information, the patient's condition and the trial's focus on catheterization methods make the patient somewhat relevant to the trial.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient's eligibility is affected by several factors. The patient has undergone cardiac catheterization via the right femoral artery, indicating potential experience with catheterization procedures. However, the patient note lacks explicit information about chronic renal failure requiring hemodialysis (inclusion criterion 0), and there is no direct evidence of the patient's medical history of central venous catheterization (inclusion criterion 1). The patient is excluded due to having undergone a procedure that may indicate a previous central venous puncture or catheterization (exclusion criterion 0). The patient's willingness to provide informed consent (inclusion criterion 3) is a positive factor, but it does not outweigh the exclusion criteria. Considering these points, the patient's eligibility for the trial is negatively impacted.",
            "eligibility_score_E": -40.0
        }
    },
    "sigir-201411": {
        "NCT01723137": {
            "relevance_explanation": "The patient presents with excruciating pain in her right arm, which aligns with the clinical trial's target condition of Acute Pain. The trial aims to measure changes in patient-reported pain scales in the emergency department. Given the patient's symptoms and the trial's objectives, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is at least 18 years of age (40 years old) and reports pain greater than 3/10. The patient is alert and able to provide informed consent and comply with the trial protocol. There is no mention of decreased level of consciousness or inability to answer questions. The patient meets the inclusion criteria and is not excluded by any of the exclusion criteria.",
            "eligibility_score_E": 90.0
        },
        "NCT01526382": {
            "relevance_explanation": "The patient note does not explicitly mention conditions like septic shock or acute respiratory distress syndrome, which are the target conditions of the clinical trial. However, the patient presents with excruciating pain in her right arm, tachypneic and tachycardic symptoms. These symptoms could be indicative of a serious underlying condition that might align with the trial\u2019s focus on critical care settings. Given the information provided in the patient note and the clinical trial description, there is a possibility that the patient\u2019s condition might be relevant to the trial\u2019s objectives. Yet, without explicit mention of septic shock or acute respiratory distress syndrome in the patient note or clear evidence of the patient meeting the specific inclusion criteria outlined in the trial protocol (e.g., heart rate of at least 90/min, respiratory rate of at least 20/min or a PaCO2 of 32mmHg or lower), it is challenging to assert a high relevance score. The patient\u2019s symptoms and presentation do not directly align with the trial\u2019s primary target conditions as described.",
            "relevance_score_R": 20.0,
            "eligibility_explanation": "The patient does not meet the inclusion criteria as outlined in the clinical trial protocol. The criteria require patients to be diagnosed with septic shock or acute respiratory distress syndrome (ARDS), or both. The patient note does not provide sufficient evidence to confirm these diagnoses. Furthermore, the patient does not exhibit signs that clearly meet the specified criteria for shock (such as a heart rate of at least 90/min) or for acute respiratory distress syndrome (such as a respiratory rate of at least 20/min or a PaCO2 of 32mmHg or lower). The patient\u2019s presentation of excruciating pain in her right arm and being tachypneic and tachycardic does not directly correspond to the trial\u2019s inclusion criteria. Additionally, the patient\u2019s blood pressure is 80/60 mmHg, which is lower than what might be expected for a patient with septic shock who would typically require vasopressor support to maintain a systolic blood pressure of at least 90mmHg. Without clear evidence of meeting the trial\u2019s inclusion criteria or explicit diagnosis of the target conditions (septic shock or ARDS), the patient cannot be considered eligible for the trial.",
            "eligibility_score_E": -20.0
        }
    },
    "sigir-201412": {
        "NCT01551498": {
            "relevance_explanation": "The patient presents with symptoms such as prolonged fatigue, hair loss, change in voice, weight gain during the previous 6 months and cold intolerance. These symptoms are commonly associated with thyroid issues. The clinical trial is focused on evaluating the effects of Anatabloc dietary supplementation on autoimmune thyroiditis. Given the patient's symptoms and the trial's target condition (Thyroiditis and Autoimmune), there is a clear connection between the patient's condition and the trial's objectives. The patient's age is also within the specified range for the trial (18-70 years). Therefore, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the age criterion (25 years old) and does not have evidence of end-stage thyroiditis. The presence of a prominent, soft and uniform anterior cervical mass could be indicative of Hashimoto's thyroiditis, which aligns with one of the inclusion criteria. However, there is no direct evidence of positive antibodies against thyroid peroxidase. The patient's eligibility is also not affected by the exclusion criteria related to smoking status or the use of specific medications. Despite some missing information (e.g., positive antibodies against thyroid peroxidase), the patient seems to meet several key inclusion criteria without being excluded by any of the mentioned exclusion criteria. Thus, the patient appears to be eligible for the trial but with some uncertainty due to missing information.",
            "eligibility_score_E": 40.0
        },
        "NCT00271427": {
            "relevance_explanation": "The patient presents with symptoms such as prolonged fatigue, hair loss, change in voice, weight gain during the previous 6 months, and cold intolerance. These symptoms are commonly associated with autoimmune thyroiditis (AIT) and Hashimoto's thyroiditis, which are the target conditions of the clinical trial. The patient also has a prominent, soft, uniform anterior cervical mass at the midline. The clinical trial aims to investigate the efficacy of selenium treatment in AIT patients. Given the patient's symptoms and the clinical trial's objectives, the patient is highly relevant to the trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient has AIT and is not using any medication other than LT4 to keep TSH in the lower half of normal range. However, the patient's eligibility is affected by the lack of information regarding other drug use and potential pathologies that may affect GIS absorption. Based on the provided information, the patient meets the inclusion criterion but lacks sufficient information to confirm full eligibility.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-201413": {
        "NCT00163709": {
            "relevance_explanation": "The patient presents with shortness of breath, which is a key symptom mentioned in the clinical trial criteria for heart failure. The trial aims to examine the effectiveness of a new heart failure blood test in patients presenting to the Emergency Department with shortness of breath. Although the patient is only 30 years old and does not meet the age criterion of being over 40 years old as specified in inclusion criterion 0, the patient's condition (shortness of breath) aligns with the target condition of the trial (Heart Failure, Congestive). Therefore, the patient is relevant to the clinical trial despite not meeting all inclusion criteria.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient does not meet the inclusion criterion 0 because she is under 40 years old. However, she does not have any of the exclusion criteria such as a traumatic cause of dyspnea, severe renal disease, cardiogenic shock, or an early transfer to another hospital. Despite the patient's relevance to the trial based on symptoms, her age disqualifies her according to the specified inclusion criteria. Thus, the patient is not eligible for the trial based on the provided criteria.",
            "eligibility_score_E": -60.0
        },
        "NCT02264769": {
            "relevance_explanation": "The patient is generally healthy and has recently given birth, which aligns with the clinical trial's focus on postpartum hemorrhage. The trial is studying the effectiveness of carbetocin at elective cesarean delivery, and the patient is undergoing this procedure. However, the patient's current presentation with shortness of breath and tachypneic and tachycardic symptoms may not be directly related to the trial's primary objective. Despite this, the patient's recent childbirth and the trial's aim to prevent postpartum hemorrhage make the trial relevant to the patient's situation.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient meets some of the inclusion criteria such as having undergone elective cesarean delivery and providing informed consent. However, the patient does not meet the criterion of being under spinal anesthesia as mentioned in inclusion criterion 0. The patient's eligibility is also affected by the presence of tachypneic and tachycardic symptoms which could indicate an underlying condition. Nevertheless, based on the provided information, the patient does not have any of the exclusion criteria such as allergy to carbetocin or oxytocin, conditions predisposing to uterine atony and postpartum hemorrhage, or hepatic, renal, and vascular disease. Given the patient's recent childbirth and the trial's focus, the patient's eligibility is compromised by not meeting all inclusion criteria and the presence of symptoms that may require further evaluation.",
            "eligibility_score_E": -30.0
        }
    },
    "sigir-201414": {
        "NCT01624545": {
            "relevance_explanation": "The patient has a gradual decrease in his level of consciousness and was involved in a car accident 3 weeks prior to his admission, which could be related to a chronic subdural hematoma. However, there is no direct evidence of a CT scan or MRI confirming the diagnosis of a chronic subdural hematoma. The patient's condition and history make the clinical trial somewhat relevant, but the lack of specific diagnostic information reduces the relevance score.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient meets some inclusion criteria: he is 85 years old and will provide informed consent. However, there is not enough information to confirm that the patient has a newly diagnosed chronic subdural hematoma by CT scan or MRI and was operated within the last 48 hours. Additionally, some exclusion criteria cannot be fully assessed due to lack of information. The patient's eligibility is uncertain due to missing details about his medical condition and treatment history.",
            "eligibility_score_E": -10.0
        },
        "NCT01869855": {
            "relevance_explanation": "The patient is 85 years old and has a gradual decrease in his level of consciousness, which could be related to a chronic subdural hematoma. The clinical trial is focused on the recurrence rate of chronic subdural hematoma after placing a subperiosteal drainage compared to a subdural drainage. Although the patient's condition is not explicitly stated as a chronic subdural hematoma in the patient note, the symptoms and the context of the clinical trial suggest a potential relevance. However, without explicit verification of a chronic subdural hematoma on cranial CT or MRI, the patient's relevance to the trial is not fully confirmed.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient meets the age criterion (at least 18 years of age) but does not have a verified chronic subdural hematoma on cranial CT or MRI as required by inclusion criterion 1. The patient is not excluded based on the provided information regarding exclusion criteria 0, 1, and 2. However, the lack of explicit verification of the chronic subdural hematoma and details about the cause or the decision for a craniotomy if needed, introduces uncertainty about the patient's full eligibility. The patient's ability to provide informed consent and comply with the trial protocol is a positive aspect but does not outweigh the missing critical information for a definitive eligibility assessment.",
            "eligibility_score_E": -40.0
        }
    },
    "sigir-201415": {
        "NCT00180739": {
            "relevance_explanation": "The patient presents with symptoms and conditions that are directly related to the clinical trial's target conditions, such as uterine fibroids and desire for future pregnancy. The patient's age is 36 years old which falls within the range of 20-40 years old as specified in the inclusion criteria. The patient has agreed to participate in the study and comply with the protocol without any practical issues. The ultrasound reports enlarged uterus with multiple cystic areas in the interior which aligns with the trial's focus on uterine fibroids. Therefore the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets some of the inclusion criteria such as having uterine fibroids and desiring pregnancy within 12 months. However the patient does not meet all the specified inclusion criteria due to the age range and lack of information regarding ovarian function and fertility history. The patient is not excluded by any of the exclusion criteria mentioned. The patient has agreed to participate and can communicate sensations which are positive points for eligibility. But due to missing information on key criteria such as ovarian function and the size and accessibility of the fibroids the patient's eligibility cannot be fully confirmed.",
            "eligibility_score_E": 40.0
        },
        "NCT00277680": {
            "relevance_explanation": "The patient presents with symptoms such as menorrhagia, bulk symptoms associated with uterine fibroids which are the target conditions of the clinical trial. The patient's condition includes amenorrhea and vaginal spotting which could be related to uterine fibroids. The physical exam reveals an 18-week sized uterus and cervical dilation of 2 cm. The ultrasound reports an enlarged uterus with multiple cystic areas in the interior and the differential diagnosis includes vesicular mole vs fibroid degeneration. These findings suggest that the patient has a condition that could potentially benefit from the treatments being compared in the clinical trial (laparoscopic occlusion of uterine vessels vs uterine fibroid embolization). Therefore the patient is relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having menorrhagia and/or bulk symptoms associated with uterine fibroids. The patient is not excluded by the exclusion criteria of malignancy (no direct evidence found) or current/planned pregnancy (negative pregnancy test). The patient is also not excluded by the criteria of small submucous fibroids suitable for hysteroscopic resection (no direct evidence found) or postmenopausal women (patient is 36 years old). However the patient is excluded by the criterion of uterus size exceeding the umbilical level (ultrasound reports an enlarged uterus of 12 cm x 9 cm x 7 cms). Despite the patient providing informed consent and complying with the trial protocol the exclusion criterion of uterus size takes precedence. Thus the patient is not fully eligible for the trial due to this specific exclusion.",
            "eligibility_score_E": -90.0
        }
    },
    "sigir-201416": {
        "NCT02238756": {
            "relevance_explanation": "The patient is a 28-year-old female with symptoms that could be related to rabies, such as neck and shoulder pain and left hand and arm paresthesias after attending a stray animal recovery campaign in California. However, the patient's condition seems to be more related to neurological disorders or seizures rather than rabies itself. The clinical trial is focused on the safety and tolerability of CV8102 alone and in combination with a rabies virus vaccine in healthy adults. Given the patient's symptoms and the trial's focus on healthy adults, the patient is not perfectly relevant to the clinical trial but does have some relevance due to the potential exposure to rabies during the animal recovery campaign.",
            "relevance_score_R": 20.0,
            "eligibility_explanation": "The patient is not eligible for the clinical trial due to several exclusion criteria. The patient has an acute disease at the time of enrolment (exclusion criterion 6) and a history of neurological disorders or seizures (exclusion criterion 12). Additionally, the patient's physical examination and laboratory results are not fully reported (inclusion criterion 1) and the patient's Body Mass Index (BMI) is not mentioned (inclusion criterion 2). The patient's use of reliable forms of contraception is also not mentioned (inclusion criterion 3). However, the patient is compliant with the protocol procedures and available for clinical follow-up (inclusion criterion 0) and has not received any licensed or non-licensed vaccines within 4 weeks prior to the administration of CV8102 alone or in combination with the licensed rabies vaccine (exclusion criterion 1).",
            "eligibility_score_E": -20.0
        },
        "NCT02374814": {
            "relevance_explanation": "The patient is relevant to the clinical trial because she has symptoms consistent with rabies infection, such as hydrophobia and spasticity. Although the patient's condition is not explicitly diagnosed as rabies in the note, the symptoms and recent exposure to stray animals during a recovery campaign in California suggest a potential risk of rabies. The clinical trial's focus on pre-exposure prophylaxis for rabies makes it relevant to the patient's situation.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient is eligible for the clinical trial based on the provided information. She meets the inclusion criterion of being a female aged between 18 and 60 years and is able to comprehend and give informed consent. There is no direct evidence of pregnancy, lactation, or childbearing potential that would exclude her. Additionally, there is no mention of participation in another clinical trial or previous history of receiving the rabies vaccine or rabies immune globulin that would disqualify her. However, the patient's anxiety and agitation could be a concern but do not clearly indicate a major psychiatric disorder that would exclude her from the trial.",
            "eligibility_score_E": 60.0
        }
    },
    "sigir-201417": {
        "NCT02556359": {
            "relevance_explanation": "The patient has a history of common variable immunodeficiency (CVID), which is related to immune deficiency. The clinical trial focuses on the consequences of DNA repair and telomere defects on the function of the immune system, specifically targeting conditions like CVID and other immune deficiencies. Although the patient's condition matches one of the inclusion criteria (CVID), the trial's primary focus is on childhood conditions and early BMF, which are not explicitly mentioned in the patient's note. However, given the relevance of CVID to the trial's objectives, the patient can be considered relevant to the study.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient meets one of the inclusion criteria by having CVID. There is no evidence to suggest the patient does not meet the other inclusion criteria or is excluded by any of the exclusion criteria mentioned. The patient is also willing to provide informed consent and comply with the trial protocol. However, the patient's age and specific condition details (like the presence of acute abdominal pain, fever, dehydration, and the outcomes of surgical intervention for a ruptured liver abscess) are not directly addressed in the eligibility criteria provided. Given the information available, the patient seems to be eligible based on the inclusion of CVID and the lack of exclusion criteria being met.",
            "eligibility_score_E": 40.0
        },
        "NCT01745731": {
            "relevance_explanation": "The patient's condition, which involves a ruptured liver abscess and hepatomegaly, aligns with the clinical trial's focus on liver regeneration and treatment for liver damage. The patient's age and willingness to provide informed consent and comply with the trial protocol also align with the trial's criteria. However\u201a the patient's history of common variable immunodeficiency (CVID) and current health status (e.g.\u201a acute abdominal pain\u201a fever\u201a dehydration) may affect their eligibility and relevance to the trial. Overall\u201a the patient's condition and circumstances make them relevant to the clinical trial\u201a but their eligibility is affected by the lack of specific information on their analytical parameters and other health aspects.",
            "relevance_score_R": 70.0,
            "eligibility_explanation": "The patient meets some inclusion criteria such as being aged \u2265 18 years and having a condition that may benefit from the trial's focus on liver regeneration. The patient also has a ruptured liver abscess and hepatomegaly\u201a which could require extended hepatic resection\u201a and they are willing to provide informed consent and comply with the trial protocol. However\u201a there is not enough information on the patient's analytical parameters (e.g.\u201a leukocyte count\u201a neutrophil count\u201a platelet count\u201a AST\u201a ALT\u201a creatinine) to fully assess their eligibility. Additionally\u201a the patient's history of CVID and current health status may impact their eligibility. The patient is not explicitly excluded by any of the exclusion criteria mentioned\u201a but the lack of detailed health information prevents a definitive assessment of their eligibility.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-201418": {
        "NCT00557219": {
            "relevance_explanation": "The patient has undergone major surgery, which can be considered as cardiac surgery, and has at least one risk factor for acute renal failure: generalized edema and low urine output. These conditions are explicitly mentioned in the trial criteria, making this trial highly relevant to the patient's current medical situation.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of having undergone cardiac surgery and having at least one risk factor for acute renal failure. The patient also has oliguria with a urine output of less than 0.2 mL/kg/hr. Despite the patient's urine output not being explicitly stated as being for over 3 hours despite adequate blood volume, the patient's condition of oliguria and the presence of other risk factors such as generalized edema suggest that the patient could benefit from the trial. The patient has provided informed consent and will comply with the trial protocol without any practical issues, which further supports eligibility. The patient does not have any of the exclusion criteria such as refused or unable to provide consent, chronic renal failure with chronic renal replacement therapy, or chronic increase of serum creatinine > 2 mg/dL.",
            "eligibility_score_E": 80.0
        },
        "NCT01260883": {
            "relevance_explanation": "The patient is a 6-month-old male infant who has undergone major surgery and is experiencing postoperative pain, which is the target condition of the clinical trial. The trial focuses on the pharmacokinetics and safety of ketorolac in postoperative infants. Given the patient's age and condition, the trial is highly relevant to the patient's situation.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being a non-prematurely-born infant admitted to the hospital following surgery aged between 2-18 months. However, the patient is 6 months old and has elevated serum creatinine (1.3 mg/dL) and blood urea nitrogen (33 mg/dL) indicating potential renal disease. This excludes the patient from the trial according to exclusion criterion 3. Despite meeting some criteria and having no reported bleeding history or coagulopathy, the patient's renal condition makes them ineligible for the trial.",
            "eligibility_score_E": -45.0
        }
    },
    "sigir-201419": {
        "NCT00256529": {
            "relevance_explanation": "The patient presents with dysphagia, which is a key inclusion criterion for the clinical trial. The trial aims to investigate eosinophilic esophagitis in patients with dysphagia. Given the patient's progressive difficulty swallowing foods and liquids and significant weight loss, this condition aligns with the trial's target conditions. Thus\uff0c the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the age criterion (52 years old) and has the ability to undergo necessary procedures as implied by their ability to provide informed consent and comply with the trial protocol. There is no direct evidence of significant cardiopulmonary disease or other contraindications to EGD and/or biopsies. However\uff0c the patient's history of heavy smoking could potentially impact their eligibility but based on the information given it does not directly exclude them. The patient is not excluded by any of the mentioned exclusion criteria.",
            "eligibility_score_E": 80.0
        },
        "NCT02509286": {
            "relevance_explanation": "The patient note describes progressive dysphagia that began several months ago, which aligns with the clinical trial's target condition of esophageal adenocarcinoma. Although the patient note does not directly mention histologically verified adenocarcinoma of the esophagus according to the UICC definition (TNM7), the symptoms described suggest a potential diagnosis of esophageal adenocarcinoma. Therefore, the patient is relevant to the clinical trial.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient meets some inclusion criteria such as being 52 years old (inclusion criterion 2) and providing informed consent (inclusion criterion 10). However, there is not enough information to determine the patient's eligibility for other criteria such as pre-treatment stage (inclusion criterion 1), ECOG Performance status (inclusion criterion 4), adequate cardiac function (inclusion criterion 5), and others. Additionally, the patient's history of heavy smoking and drinking and significant weight loss may indicate potential exclusion criteria such as advanced inoperable or metastatic esophageal adenocarcinoma (exclusion criterion 1) or clinically significant cardiac disease (exclusion criterion 5). Without further information, the patient's eligibility cannot be fully determined.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-201420": {
        "NCT01594385": {
            "relevance_explanation": "The patient has traumatic injuries, including upper and lower extremity fractures and is undergoing open abdomen damage control management. The clinical trial is focused on testing the effects of Seprafilm adhesion barrier on patients with traumatic injuries undergoing open abdomen damage control management. Given the patient's condition and the trial's objectives  the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for the clinical trial: she has traumatic injuries and is undergoing open abdomen damage control management  she is older than 18 years  and her life expectancy is likely longer than 48 hours given the context of her ER admission and treatment. Additionally  the patient is not excluded by any of the exclusion criteria (not a prisoner  not pregnant, and older than 18 years). The patient also provides informed consent and will comply with the trial protocol without practical issues. Therefore  the patient is fully eligible for the clinical trial.",
            "eligibility_score_E": 90.0
        },
        "NCT02255487": {
            "relevance_explanation": "The patient has experienced abdominal trauma requiring open abdominal laparotomy, which is the target condition of the clinical trial. The trial aims to compare the rate of surgical site infections in patients with abdominal trauma or acute surgical abdomen. Given the patient's condition and the trial's objectives, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria: she is a 32-year-old woman who has experienced abdominal trauma and will provide informed consent. She also meets the criteria for having abdominal trauma requiring open abdominal laparotomy. There is no mention of her being excluded by any of the exclusion criteria such as known allergy to Chlorhexidine Gluconate (CHG), Estimated Abbreviated Injury Scale (AIS) score of six (6) at the time of surgery, American Society of Anesthesiologists Physical Status Classification (ASA) score of five (5) or greater, being pregnant and/or breast feeding, damage control laparotomy, abdominal incision created prior to operating room, or currently enrolled in an ongoing interventional randomized clinical trial. Therefore, the patient is eligible for the clinical trial.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201421": {
        "NCT01520155": {
            "relevance_explanation": "The patient's symptoms, such as progressive arthralgias, malaise, alopecia, rash, and swelling, along with lab results showing normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA, strongly suggest a diagnosis of Systemic Lupus Erythematosus (SLE). The clinical trial, titled CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE), specifically targets patients with Systemic Lupus Erythematosus, making the patient highly relevant to the trial.",
            "relevance_score_R": 95.0,
            "eligibility_explanation": "The patient meets the inclusion criterion for having Systemic Lupus Erythematosus as evidenced by their symptoms and lab results. There is no mention of the patient being without systemic Lupus erythematosus, which would be an exclusion criterion. The patient's ability to provide informed consent and comply with the trial protocol also supports their eligibility. However, the presence of renal affection (indicated by protein and RBC casts in the urine) might be a consideration but is not explicitly listed as an exclusion criterion in the provided information. Thus, based on the given criteria, the patient appears to be eligible for the trial.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201422": {
        "NCT00723788": {
            "relevance_explanation": "The patient is a 15-year-old girl presenting with abdominal pain, which gradually localized to the right lower quadrant. The clinical trial is focused on Magnetic Resonance Imaging (MRI) of Appendicitis in Children. Given that the patient's symptoms and diagnosis of appendicitis align with the target conditions of the trial, this trial is highly relevant to the patient. The patient's age is within the specified range of 8-18 years, and she is being referred from the emergency department for suspected appendicitis, further increasing the relevance.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being between 8-18 years old and is referred from the emergency department for suspected appendicitis. There is no mention of the patient failing to pass MRI metal screening or having claustrophobia, which are exclusion criteria. Additionally, the patient has agreed to provide informed consent and will comply with the trial protocol without any practical issues. This suggests that the patient is eligible for the trial based on the provided information.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201423": {
        "NCT00170222": {
            "relevance_explanation": "The patient presents with symptoms such as cough, shortness of breath, productive cough, and purulent sputum, which are indicative of an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD). The clinical trial is focused on the treatment of acute exacerbations of COPD using antibiotics. Given the patient's symptoms and the trial's objectives, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets several inclusion criteria for the clinical trial: he has an acute exacerbation of COPD type I or II according to GOLD (inclusion criterion 0), he is able to perform lung function tests (inclusion criterion 1), and he is able to take oral medication (inclusion criterion 2). Additionally, the patient is not excluded by any of the exclusion criteria: he is not pregnant or lactating (exclusion criterion 0), he has not been pretreated with antibiotics for the present exacerbation (exclusion criterion 1), and he does not have any of the other exclusion conditions such as recent or unresolved lung malignancy (exclusion criterion 6) or significant gastrointestinal conditions (exclusion criterion 8). However, the patient is excluded due to having other diseases that may require antibiotic therapy (exclusion criterion 7).",
            "eligibility_score_E": -10.0
        },
        "NCT02219360": {
            "relevance_explanation": "The patient presents with symptoms such as cough and shortness of breath, which are indicative of acute exacerbation of chronic obstructive pulmonary disease (COPD). The patient's past medical history of heavy smoking and the presence of a barrel-shaped chest with diffuse rales over his lungs further support the relevance to the clinical trial. The patient's condition and symptoms align with the target conditions of the trial, making this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for being hospitalized with acute exacerbation of COPD and is above 40 years old. The patient is not excluded by any of the exclusion criteria such as congestive heart failure, lung cancer, active pulmonary tuberculosis, pulmonary thromboembolism, interstitial lung diseases, serious cardiac failure, renal insufficiency, or hepatic dysfunction. The patient's symptoms began about a week prior to his admission and he has been using his home oxygen for the past 24 hours, indicating a need for hospitalization due to acute exacerbation of COPD. The patient will provide informed consent and will comply with the trial protocol without any practical issues.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201424": {
        "NCT02229695": {
            "relevance_explanation": "The patient is an adult male undergoing emergency laparotomy due to abdominal trauma, which aligns with the trial's target conditions of intra-abdominal hypertension and abdominal compartment syndrome. The patient's condition of extended intraperitoneal hemorrhage due to spleen rupture and the need for temporary abdominal closure makes this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being an adult male over 18 years old undergoing emergency laparotomy with temporary abdominal closure. Although the patient's survival estimate is not explicitly mentioned, the patient's presentation with acute abdominal pain and hemodynamic instability (BP: 60/30 mmHg, HR: 140/min) may indicate a severe condition. However, based on the provided information, the patient is not excluded by the exclusion criterion of not surviving 24 hours. The patient's ability to provide informed consent and comply with the trial protocol also supports eligibility.",
            "eligibility_score_E": 80.0
        },
        "NCT01771861": {
            "relevance_explanation": "The patient presented to the ER with acute abdominal pain due to a blunt trauma from a bike fall, which aligns with the clinical trial's target conditions of trauma and injuries. The patient's subsequent emergency procedures and diagnosis of extended intraperitoneal hemorrhage due to spleen rupture further support the relevance to the trial. The trial aims to evaluate the predictive properties of the trauma team activation protocol and its individual criteria, which could be informed by the patient's case.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the first inclusion criterion by being admitted with the trauma team. Although the patient's Injury Severity Score is not explicitly mentioned, the presence of severe symptoms and diagnosis suggest a high severity score. However, there is not enough information to definitively determine if the patient meets the second inclusion criterion of having an Injury Severity Score >15. Additionally, there is insufficient information regarding the timing of the patient's admission and potential secondary transfer to assess the exclusion criterion of secondary admittance (transfers) >24 hours post-injury.",
            "eligibility_score_E": 40.0
        }
    },
    "sigir-201425": {
        "NCT00282269": {
            "relevance_explanation": "The patient has a severe traumatic brain injury, which is the target condition of the clinical trial. The patient's Glasgow Coma Scale (GCS) was 6/15 and the pupils were asymmetrical  indicating an abnormal CT scan would likely be found. The patient is within the age range of 1 to 16 years. The patient's condition and age make this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having a severe traumatic brain injury as defined by a GCS \u2264 8. The patient is also within the age range of 1 to 16 years. However, there is not enough information to determine if the patient was randomized by 6 hours after injury and if the patient has more than mild neurodevelopmental disability prior to injury. The patient is mechanically ventilated is not directly mentioned in the note. Despite these uncertainties, the patient does not meet any of the exclusion criteria based on the provided information.",
            "eligibility_score_E": 40.0
        }
    },
    "sigir-201427": {
        "NCT01187901": {
            "relevance_explanation": "The patient is relevant to the clinical trial because they have a family history of multiple polyps, which is a key criterion for the trial. The patient's age of 21 also meets the age requirement of being 18 years or older. Additionally, the patient has dozens of small colonic polyps within the rectosigmoid area as found during the sigmoidoscopy. These factors align with the trial's focus on familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is eligible for the trial because they meet several key inclusion criteria: they are over 18 years old and have a clinical diagnosis relevant to FAP or AFAP due to their family history and personal findings of colonic polyps. The patient will provide informed consent and comply with the trial protocol. However, there is not enough information to fully confirm eligibility regarding some criteria such as the presence of duodenal polyps with a sum of diameters \u2265 5mm, minimum time since any major surgery, WHO performance status, and adequate bone marrow and liver function. Despite these uncertainties, the patient does not meet any of the exclusion criteria mentioned.",
            "eligibility_score_E": 40.0
        },
        "NCT01713881": {
            "relevance_explanation": "The patient has adenomas found on screening/surveillance colonoscopy, which is a key criterion for the clinical trial. The trial focuses on colon polyp surveillance and the patient's condition aligns with the target conditions of the trial. The patient's family history and personal medical history of colon polyps also increase the relevance to the trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of having adenomas found on screening/surveillance colonoscopy and is greater than 18 years old. There is no mention of the patient being diagnosed with IBD or any other exclusion criteria being met. However, the patient's current condition and willingness to participate as mentioned in the patient note suggest a high likelihood of eligibility.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-201429": {
        "NCT00703417": {
            "relevance_explanation": "The patient is a postmenopausal female with concerns about osteoporosis, which aligns with the clinical trial's focus on osteoporosis in type II diabetes patients. However, the patient's age (51 years old) is outside the trial's specified age range (55-75 years old). Additionally, the patient's diet-controlled diabetes mellitus may not meet the trial's criteria for type II diabetes. Despite these discrepancies, the patient's interest in osteoporosis prevention and her postmenopausal status make her somewhat relevant to the trial.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient does not meet the inclusion criteria for the clinical trial due to her age being outside the specified range and her diabetes not meeting the defined criteria for type II diabetes. Furthermore, her significant hypertension and diet-controlled diabetes mellitus could affect bone metabolism, potentially excluding her based on exclusion criteria related to diseases that may impact bone health. However, she is able to move without walkers and has no mentioned history of long periods of inactivity or severe neuropathic disease. The lack of specific information about her BMI, fracture history, and other potential exclusions means that while she is not clearly eligible, there are also factors that do not strictly disqualify her based on the provided information alone.",
            "eligibility_score_E": -40.0
        },
        "NCT01978834": {
            "relevance_explanation": "The patient is a 51-year-old woman concerned about osteoporosis, which is the target condition of the clinical trial. The trial aims to validate a novel ultrasound device for diagnosing osteoporosis and evaluating bone mineral density. Given the patient's concern and the trial's objectives, the patient is highly relevant to the clinical trial. The patient's age falls within the specified range of 50 to 89 years, and she is female, meeting the inclusion criteria. Additionally, the patient has a history of significant hypertension and diet-controlled diabetes mellitus, and she is a smoker, but these factors do not exclude her from the trial based on the provided criterion-level eligibility predictions.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of being female and within the age range of 50 to 89 years. She has not opted out of being contacted for research and does not have cognitive impairment. The patient is also able to sign the consent form and does not have any conditions that would make the measurement of hip BMD infeasible, such as bilateral hip replacement surgeries or inability to have central DXA due to body weight. Furthermore, she does not have open leg or arm wounds at sites where ultrasound measurements are supposed to be taken. However, the patient's history of hypertension and diabetes mellitus, as well as her smoking status, may be considered in the context of the trial's focus on osteoporosis. Despite these factors, the patient's eligibility is primarily determined by her ability to meet the trial's inclusion and exclusion criteria, which she does. Thus, based on the provided information, the patient is eligible for the trial.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-201430": {
        "NCT02273232": {
            "relevance_explanation": "The patient has moderate Peripheral Arterial Disease (PVD), which is the target condition of the clinical trial. The patient's symptoms, such as increasing calf pain when walking uphill and diminished pulses at the dorsalis pedis, are consistent with the condition. The trial aims to investigate the effects of Remote Ischemic Preconditioning (RIPC) on patients with moderate PVD. Given the patient's condition and symptoms, this trial is highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for the trial, having known moderate PVD and symptoms matching Rutherford stage 2 and Fontaine stage 2a. However, the patient had an uncomplicated myocardial infarction 2 years earlier and a transient ischemic attack 6 months ago, which may indicate a severe cardiac condition and thus excludes the patient from the trial. Despite this, the patient does not have other exclusion criteria such as upper limb PVD, severe respiratory condition, or previous history of upper limb deep vein thrombosis. The patient is also not taking medications that could affect RIPC and does not have contraindications for MRA or pregnancy. Considering these factors, the patient's eligibility is negatively impacted by the severe cardiac condition but is not entirely disqualified by other factors.",
            "eligibility_score_E": -45.0
        },
        "NCT00721006": {
            "relevance_explanation": "The patient's condition of severe leg ischemia, as indicated by increasing calf pain when walking uphill and a history of myocardial infarction and transient ischemic attack, aligns with the clinical trial's target conditions of Critical Limb Ischemia and Severe Leg Ischemia. The patient's symptoms and medical history suggest a high relevance to the trial's purpose of treating severe leg ischemia through combination stem cell therapy.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets several inclusion criteria such as being older than 18 years of age and having limb ischemia with resting ischemic pain and/or claudication. However, the patient is excluded due to having any illness which might affect the patient's survival after enrollment in the protocol (history of myocardial infarction and transient ischemic attack) and having uncontrolled blood pressure. These conditions could interfere with the patient's ability to comply with the protocol or compromise the patient's safety.",
            "eligibility_score_E": -45.0
        }
    },
    "sigir-20151": {
        "NCT01142245": {
            "relevance_explanation": "The patient is relevant to the clinical trial because the patient's condition, which includes vomiting with a 'coffee ground' appearance and decreased mental status, aligns with the target conditions of the trial (bleeding and peptic ulcers). Although there is no direct information about the type of ulcer bleeding in the patient note, the symptoms suggest peptic ulcer hemorrhage. The trial focuses on patients with peptic ulcer hemorrhage who are at risk for recurrent bleeding. Given the patient's presentation and the trial's objectives and inclusion criteria (such as age \u2265 18 and confirmed ulcer bleeding with Forrest Ia, Ib, IIa, IIb), the patient appears to be a suitable candidate for the trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is eligible for the clinical trial because the patient meets several key inclusion criteria: the patient is 44 years old (meets the age criterion of \u2265 18), has vomiting with a 'coffee ground' appearance indicating possible peptic ulcer hemorrhage (though not directly confirmed), received endoscopic therapy as indicated by 'endoscopic control of bleeding', and will provide informed consent. The patient does not meet any of the exclusion criteria mentioned: no consent is an issue since the patient will provide informed consent, the patient does not have Forrest IIc or III ulcers (indicating minimal risk for rebleeding), did not have unsuccessful endoscopic treatment or severe bleeding requiring immediate surgery, is not moribund to the point of not considering active treatment of any form, and does not have polytrauma, severe injury, unconsciousness, burns, or need for continuous artificial ventilation. The only criterion not fully met is the specific type of ulcer bleeding (Forrest Ia, Ib, IIa, IIb), but given the clinical context and symptoms described (vomiting with 'coffee ground' appearance), it is reasonable to consider the patient as having a condition that aligns with the trial's focus on peptic ulcer hemorrhage.",
            "eligibility_score_E": 80.0
        },
        "NCT00843063": {
            "relevance_explanation": "The patient note describes a 44-year-old male with symptoms of vomiting with 'coffee ground' appearance, which could be indicative of upper GI bleeding. The clinical trial focuses on preventing recurrent aspirin-induced peptic ulcers/erosions. Although the patient note does not directly mention peptic ulcers or erosions due to aspirin use within the specified dose range (80 mg to 320 mg) or other explicit inclusion criteria like endoscopy results showing ulcers or erosions of a certain size, the presentation of vomiting with 'coffee ground' appearance suggests a possible upper GI bleed which might be related to peptic ulcers or erosions. Thus, the patient could be considered relevant to the trial based on the symptoms described.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient is 44 years old which meets the age criterion of 18 years or older. However, there is not enough information in the patient note to confirm other inclusion criteria such as the presence of peptic ulcers or erosions while on low-dose aspirin or the requirement for continuous low-dose aspirin for secondary prevention of coronary heart disease, peripheral vascular disease, and ischemic stroke or transient ischemic attacks. The patient does not have direct evidence of exclusion criteria such as concurrent erosive or ulcerative esophagitis, pyloric stenosis, previous gastric or duodenal surgery other than oversewing of a perforation, thrombocytopenia, renal failure with estimated creatinine clearance less than 10 ml/min, active cancer, known allergic reactions to aspirin, famotidine or pantoprazole, pregnancy or lactation (as the patient is male), psychosomatic disorder that would affect participation, or planned co-prescription of nonsteriodal anti-inflammatory drugs corticosteriod or anticoagulant. Despite the lack of direct evidence for some criteria, the absence of explicit exclusion criteria and the potential relevance based on symptoms presented suggest the patient could be eligible but more information is needed to fully assess eligibility.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-20152": {
        "NCT02532452": {
            "relevance_explanation": "The patient is immunocompromised with evidence of viral infection or reactivation, as indicated by the presence of owl's eye inclusion bodies in the nuclei of infection cells, which suggests a viral infection. The clinical trial is focused on viral specific T-cells for patients with viral infections, making the patient highly relevant to the trial. The patient's age and ability to provide informed consent also align with the trial's criteria.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets several inclusion criteria: they are immunocompromised with evidence of viral infection or reactivation (inclusion criterion 0), their age is greater than 1 day (inclusion criterion 1), and they can provide informed consent (inclusion criterion 5). Additionally, the patient is on prednisone which may allow for tapering of steroids to < 0.5mg/kg or other steroid equivalent (inclusion criterion 3). However, there is not enough information regarding the patient having a stem cell transplant (inclusion criterion 2) and their ability to receive CTL infusion in Cincinnati (inclusion criterion 4). The patient is not excluded by any of the exclusion criteria mentioned.",
            "eligibility_score_E": 60.0
        },
        "NCT00034437": {
            "relevance_explanation": "The patient presents with symptoms and a condition (cytomegalovirus infection) that is directly relevant to the clinical trial's target condition. The trial focuses on immune responses to cytomegalovirus, which is indicated by the presence of owl's eye inclusion bodies in the BAL fluid examination. This suggests that the patient has been exposed to CMV and is experiencing a reactivation of the virus due to immunosuppression. The patient's age (62 years) is slightly outside the trial's specified age range (18-65) but does not inherently make the trial irrelevant. Given the direct relevance of the patient's condition to the trial's objectives and the potential for the patient to provide valuable insights into immune responses against CMV despite the age discrepancy, the trial is considered relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is not fully eligible for the trial. Although the patient will provide informed consent and comply with the trial protocol, and there is no mention of exclusion criteria such as abnormal blood counts, known history of heart, lung, kidney, liver, or bleeding disorders, HIV infection, or history of intravenous drug use, the patient's age (62 years) is outside the specified age range of 18-65. Moreover, the patient is on immunosuppressive medications, indicating an immunodeficiency state, which is an exclusion criterion. Thus, despite the relevance of the trial to the patient's condition, the patient is ineligible due to age and immunodeficiency state.",
            "eligibility_score_E": -45.0
        }
    },
    "sigir-20153": {
        "NCT01139632": {
            "relevance_explanation": "The patient presents with symptoms such as shortness of breath, tachypnea, and left-sided chest pain that worsens with inspiration. These symptoms could be indicative of acute coronary syndrome presentation or other cardiovascular issues, which are relevant to the clinical trial's focus on coronary artery disease in patients with Nonalcoholic Fatty Liver Disease (NAFLD). However, the patient's primary condition of concern in the note provided does not directly align with NAFLD or coronary artery disease as the primary diagnosis. The patient is at intermediate risk for significant CAD and was admitted to the hospital with the diagnosis of chest pain, making the trial somewhat relevant due to the overlap in cardiovascular risk factors.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient meets several inclusion criteria: being at intermediate risk for significant CAD and admitted with chest pain (criterion 0), being a 65-year-old male (criterion 1), and able to provide written informed consent (criterion 2). However, the patient is excluded due to the presentation of acute onset symptoms that could indicate acute coronary syndrome (exclusion criterion 0). Despite meeting some criteria, the patient's exclusion due to potential acute coronary syndrome presentation outweighs these factors for eligibility in this specific trial.",
            "eligibility_score_E": -40.0
        },
        "NCT01326507": {
            "relevance_explanation": "The patient presents with acute onset of shortness of breath, tachypnea, and left-sided chest pain that worsens with inspiration, which are symptoms consistent with pulmonary embolism. The patient also has a recent history of right total hip replacement and was unable to begin physical therapy and rehabilitation, which increases the risk of pulmonary embolism. The clinical trial is focused on the prognostic value of heart-type fatty acid-binding protein (h-FABP) in acute pulmonary embolism, making this trial highly relevant to the patient's condition.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having acute pulmonary embolism diagnosed in the emergency department. The patient is not under guardianship, has no mention of lacking social insurance (but can be inferred to have insurance due to recent surgery), is not pregnant, and is willing to provide informed consent. There is no mention of myocardial infarction in the 10 days before pulmonary embolism. Therefore, the patient is eligible for the clinical trial.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-20154": {
        "NCT00844987": {
            "relevance_explanation": "The patient presents with symptoms of acute coronary syndrome (ACS), including chest pain and shortness of breath, which aligns with the target condition of the clinical trial. The patient's EKG results show ST-segment elevations, and the coronary angiography results indicate no stenosis or clinically significant disease. These findings suggest that the patient's condition is relevant to the trial's focus on ACS. Furthermore, the patient's left ventriculography and transthoracic echocardiogram results reveal severe segmental left ventricular dysfunction and mildly impaired left ventricular systolic function, respectively. These results are pertinent to the trial's objectives, which involve assessing serum and plasma concentrations of growth factors in relation to markers of myocardial injury and estimating the value of these factors in predicting cardiovascular complications. Therefore, the patient's condition is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets some of the inclusion criteria for the clinical trial, such as having typical chest pain and ST segment elevation in the EKG. Additionally, the patient had an indication for coronary angiography and provided informed consent. However, the patient has a known past history of myocardial infarction, which is an exclusion criterion for the trial. Despite meeting some inclusion criteria, this exclusion criterion makes the patient ineligible for the trial. The patient's other health issues, such as hypertension, renal-artery stenosis with chronic renal insufficiency, hypercholesterolemia, osteoporosis, and dementia, do not directly impact the eligibility criteria for this specific trial but do indicate a complex medical history that could influence the patient's suitability for certain aspects of the trial.",
            "eligibility_score_E": -45.0
        },
        "NCT01243255": {
            "relevance_explanation": "The patient note explicitly mentions hypercholesterolemia, which is the target condition of the clinical trial. This makes the patient highly relevant to the trial. The patient is also on lipid-lowering drug treatment as mentioned in the patient note. However, there is limited information about the duration of this treatment and any recent changes to the treatment regimen. Despite these limitations, the patient's condition and current treatment make them relevant to the trial.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being on lipid-lowering drug treatment. However, there is not enough information to confirm that the patient has been on this treatment for at least 3 months or that there have been no changes to the lipid-lowering drug/dose for a minimum of 6 weeks prior to enrolment. Additionally, while the patient will provide informed consent, there is no mention of a blood sample being taken for lipid profile and glucose within the specified timeframe. Given these uncertainties and the lack of explicit confirmation of all eligibility criteria, the patient's eligibility score is reduced but not entirely excluded due to the relevance of their condition to the trial.",
            "eligibility_score_E": 20.0
        }
    },
    "sigir-20155": {
        "NCT02118818": {
            "relevance_explanation": "The patient presents with symptoms such as joint pain, fatigue, and intermittent fevers which could be indicative of an autoimmune disease like Rheumatic Heart Disease (RHD). However, the patient note does not explicitly mention a history of untreated pharyngeal Streptococcus pyogenes infection or the development of rheumatic fever (RF) which is a prerequisite for RHD. The patient's symptoms of joint pain and swelling could align with the clinical presentation of RF or RHD but the direct link to RHD as specified in the clinical trial is not clearly established in the patient note.",
            "relevance_score_R": 20.0,
            "eligibility_explanation": "The patient does not meet the inclusion criterion of having clinical and echocardiographic signs of RHD using WHF criteria as this information is not provided in the patient note. Additionally, there is no mention of congenital heart disease which would exclude the patient. However, without explicit evidence of RHD or its precursor (rheumatic fever) and without meeting the specified inclusion criteria, the patient cannot be considered fully eligible for the trial.",
            "eligibility_score_E": -20.0
        },
        "NCT02407106": {
            "relevance_explanation": "The patient note describes a 31-year-old woman with symptoms of joint pain, fatigue, and intermittent fevers. However\uff0c the clinical trial is focused on the efficacy of BLIS K12 as a preventive measure for rheumatic children with a target condition of rheumatic fever. The patient's symptoms do not explicitly align with the target condition of the trial\uff0c which is specifically designed for children who have had an episode of rheumatic fever. The patient's presentation of joint pain and swelling could be indicative of an inflammatory or rheumatic condition but it does not directly match the criteria for rheumatic fever as described in the clinical trial. Therefore\uff0c the patient is not highly relevant to this specific clinical trial.",
            "relevance_score_R": 0.0,
            "eligibility_explanation": "Given the patient's age and the fact that the trial is targeted at children who have had an episode of rheumatic fever\uff0c the patient does not meet the basic demographic criteria for the trial. Additionally\uff0c the patient note does not provide sufficient information to confirm a diagnosis of rheumatic fever or any previous episode that would make her eligible for a trial focused on preventing streptococcal throat infections in the context of rheumatic fever. The patient's willingness to provide informed consent and comply with the trial protocol is noted but is not sufficient to overcome the lack of relevance to the trial's specific inclusion criteria.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-20156": {
        "NCT02375451": {
            "relevance_explanation": "The patient presents with symptoms such as weight loss, sweating, insomnia, and diarrhea, and also reports an increased appetite and heart racing, which could be indicative of hyperthyroidism. The clinical trial is focused on the effect of radioiodine therapy on salivary function in patients with thyroid disease, including hyperthyroidism. Although the patient note does not explicitly mention a diagnosis of hyperthyroidism or thyroid cancer, the symptoms described are consistent with hyperthyroidism, making this trial relevant to the patient's condition.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient's eligibility for the trial cannot be fully determined based on the provided information. The inclusion criteria mention patients who have been treated with radioiodine therapy and those who have never received it, but the patient note does not specify whether the patient has received radioiodine therapy. Additionally, the exclusion criterion regarding non-English speaking subjects is not applicable as the patient note is in English. However, without explicit information on radioiodine therapy treatment, the patient's eligibility remains uncertain.",
            "eligibility_score_E": 0.0
        },
        "NCT01717352": {
            "relevance_explanation": "The patient presents with symptoms such as weight loss, sweating, insomnia and diarrhea. These symptoms can be associated with overweight and obesity which are the target conditions of the clinical trial. The patient's age is within the range of 21 to 65 and the patient will provide informed consent and comply with the trial protocol. However the patient's current condition of weight loss may not align perfectly with the target conditions of overweight and obesity. Therefore the patient is somewhat relevant to the clinical trial.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient meets the age inclusion criterion. However the patient's BMI is not directly mentioned and it can't be confirmed if the patient's BMI is within the range of 25 to 45. The patient reports sleeping issues (insomnia) which implies sleep less than 7 hours most nights making the patient not included in the sleep criterion. There is no direct evidence that the patient is using medications affecting sleep or has sleep apnea. The patient's work schedule is not mentioned. Considering the provided information the patient is not fully eligible for the clinical trial due to lack of information about some criteria and not meeting the sleep criterion.",
            "eligibility_score_E": -30.0
        }
    },
    "sigir-20157": {
        "NCT02633449": {
            "relevance_explanation": "The patient presents with symptoms of fatigue, increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork and feelings of guilt for not spending more time with her family. These symptoms align with the target condition of the clinical trial: Major Depression. The patient's condition is explicitly mentioned in the trial criteria as unipolar major depressive disorder. Therefore, this trial is highly relevant to the patient.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having unipolar major depressive disorder. The patient also does not have any significant past medical history or current conditions that would exclude her from the trial based on the provided exclusion criteria. The laboratory tests are within normal limits and there is no mention of manic episodes, psychotic symptoms, or recent treatments with psychotherapy or electroconvulsive therapy that would disqualify her. The patient has also agreed to provide informed consent and comply with the trial protocol. Therefore, the patient appears to be eligible for the trial.",
            "eligibility_score_E": 90.0
        },
        "NCT01632319": {
            "relevance_explanation": "The patient is a 20-year-old female college student experiencing symptoms such as increased sleep and appetite, difficulty concentrating, and feelings of guilt, which may indicate depressive symptoms. These symptoms align with the clinical trial's target conditions of depression. However, there is no direct evidence of binge drinking episodes in the patient note, which is a crucial criterion for the clinical trial. Despite this, the patient's symptoms and current enrollment in college as an undergraduate student make her relevant to the trial's purpose of investigating therapy effectiveness for undergraduate college students experiencing depressive symptoms.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient meets some inclusion criteria, such as being currently enrolled in college as an undergraduate student and being within the age range of 18-24 years. However, there is not enough information to confirm the presence of at least mild depressive symptoms (BDI-II score) or binge drinking episodes in the past month, which are essential criteria for eligibility. The patient does not meet the exclusion criteria based on the provided information.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-20158": {
        "NCT00393913": {
            "relevance_explanation": "The patient's symptoms, including nighttime snoring, pauses in breathing, and restlessness with nighttime awakenings, align with the target conditions of the clinical trial, which focuses on sleep apnea and its impact on daytime alertness. The patient's declining grades, lack of attention, and excessive sleepiness during class further support the relevance of this trial to the patient's condition. Therefore, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion 0 by experiencing symptoms of OSAS, including snoring and sleepiness. Although the patient's medical history is stable, which supports inclusion criterion 1, there is no direct evidence that the patient's condition is exclusively OSAS, and not another sleep disorder. However, given the information provided, the patient does not appear to be excluded by any of the exclusion criteria, including suspected diagnosis of another sleep disorder, medically unstable health conditions, use of psychotropic medications, recent recreational drug use or alcohol abuse, pregnancy, inability to communicate, or visual, hearing, or cognitive impairment. The patient's ability to provide informed consent and comply with the trial protocol also supports eligibility. Thus, considering the criteria provided, the patient appears to be eligible for the trial.",
            "eligibility_score_E": 80.0
        },
        "NCT02562040": {
            "relevance_explanation": "The patient's condition of nighttime snoring, pauses in breathing, and restlessness with nighttime awakenings aligns with the clinical trial's target condition of sleep-disordered breathing. The patient's symptoms and the trial's objectives are closely related, making the patient highly relevant to the trial. The patient's declining grades and excessive sleepiness during class further support the relevance of the trial to the patient's condition.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having mild sleep-disordered breathing (MSDB) as defined by habitual snoring occurring most nights per week for at least three months. However, there is not enough information to confirm the patient's eligibility based on other criteria such as the absence of obstructive sleep apnea or the presence of tonsillar hypertrophy. The patient is deemed eligible based on the provided information but lacks confirmation on some critical aspects. The patient's ability to provide informed consent and comply with the trial protocol is a positive factor for eligibility.",
            "eligibility_score_E": 40.0
        }
    },
    "sigir-20159": {
        "NCT01766830": {
            "relevance_explanation": "The patient's symptoms, such as myalgia, cough, and shortness of breath, along with the history of low-grade fever, abdominal pain, and diarrhea, align with the target conditions of the clinical trial, which focuses on tropical diseases in patients with persistent fever. The patient's recent stay on a farm that raises domestic pigs also increases the likelihood of exposure to zoonotic diseases, some of which are targeted by the trial. Although the patient's current condition and symptoms do not directly match all the diseases listed in the trial, the presence of fever for more than a week and other symptoms makes the patient relevant for a trial aiming to develop diagnostic tools for tropical diseases.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of having a fever for \u2265 1 week and is \u2265 5 years old. The patient is also able to give written informed consent and there is no indication that the patient is unable to comply with the study requirements. Furthermore, there is no existing laboratory-confirmed diagnosis mentioned, and while the patient shows signs of illness, there is no explicit mention of needing immediate intensive care due to shock or respiratory distress that would exclude them from the trial. Therefore, based on the provided information, the patient appears to be eligible for the trial.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-201510": {
        "NCT02340533": {
            "relevance_explanation": "The patient complains of severe premenstrual and menstrual pelvic pain, which is related to pelvic congestion, making this trial highly relevant as it targets adenomyosis which could be a cause of her symptoms. The patient's past medical history of infertility treatment and ectopic pregnancy also suggests potential underlying conditions that could be related to adenomyosis.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being a female complaining of pelvic congestion symptoms such as dysmenorrhea. Additionally, the patient has provided informed consent and will comply with the trial protocol, indicating no refusal to get enrolled in the study. Thus, the patient is eligible based on the provided criteria.",
            "eligibility_score_E": 90.0
        },
        "NCT01377519": {
            "relevance_explanation": "The patient note explicitly mentions symptoms such as severe premenstrual and menstrual pelvic pain, heavy and irregular periods and occasional spotting between periods. These symptoms align with the target conditions of the clinical trial which focuses on uterine fibroids. The patient's age and premenopausal status also match the trial's inclusion criteria. Therefore) the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets several inclusion criteria: she is over 18 years old) premenopausal) and has symptomatic fibroids. However) her eligibility is affected by exclusion criteria. Notably) the desire for future fertility is contradicted by the trial's focus on treating fibroids without considering fertility preservation. Other exclusion criteria such as current pregnancy) significant anemia) history of venous thromboembolism) and certain fibroid characteristics are not applicable based on the provided information. Despite meeting key inclusion criteria) the patient's desire for future fertility and some lacking information on other exclusion criteria complicate her eligibility.",
            "eligibility_score_E": -45.0
        }
    },
    "sigir-201511": {
        "NCT01862510": {
            "relevance_explanation": "The patient's symptoms such as being markedly more sensitive to the cold, tiredness, decreased appetite, constipation, hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin are all indicative of hypothyroidism. The clinical trial is focused on detecting celiac disease in patients with hypothyroidism and evaluating the risk of celiac disease in hypothyroid patients requiring elevated doses of levothyroxine. Given the patient's condition and the trial's objectives, there is a strong relevance between the patient's needs and the trial's goals.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having hypothyroidism and requiring thyroid replacement therapy. There is no mention of the patient having undergone surgical resection of thyroid tissue, neck irradiation, radioactive iodine therapy, or prior medical treatment with specific medications that would exclude them from the trial. The patient's ability to provide informed consent and comply with the trial protocol also supports their eligibility. Thus, the patient appears to be eligible for the trial based on the provided criteria.",
            "eligibility_score_E": 90.0
        },
        "NCT01197183": {
            "relevance_explanation": "The patient note explicitly mentions symptoms such as being markedly more sensitive to the cold, tiredness, decreased appetite, constipation, hyporeflexia, and dry skin, which are all characteristic of hypothyroidism. The clinical trial is focused on the initial treatment of hypothyroidism in France, making the patient highly relevant to the trial. The patient's recent diagnosis with hypothyroidism within the last 6 months and the availability of data related to the diagnosis further support the relevance.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of being a recently diagnosed hypothyroid subject and has given informed consent for participation. There is no mention of the patient being in another clinical trial in the last 3 months, which would have excluded them. Although the patient exhibits symptoms like tiredness and slow movement, these do not directly indicate a major risk of not being able to follow-up until the next TSH level. The patient note does not mention any contraindications to L\u00e9vothyrox, which further supports their eligibility.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-201512": {
        "NCT02418169": {
            "relevance_explanation": "The patient has a severe traumatic brain injury, as indicated by the symptoms of clear fluid dripping from the nose, severe headache and fever after an automobile accident. The patient also has a skull fracture and nuchal rigidity was found on physical examination. These conditions are explicitly mentioned in the trial criteria as target conditions (Brain Injuries, Skull Fractures) and the patient's symptoms align with the purpose of the study to evaluate the association between traumatic brain injuries and craniofacial or skull fractures. Therefore\uff0c this trial is highly relevant to the patient.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having a severe traumatic brain injury and a skull fracture. Although the patient's GCS score is not explicitly mentioned as 8 or less\uff0c the presence of severe symptoms and the need for further diagnostic and therapeutic considerations suggest that the patient could be within the scope of the study. The patient did not die before admission to the hospital and will provide informed consent and comply with the trial protocol. However\uff0c the patient's eligibility is not fully confirmed due to the lack of explicit information regarding the GCS score and other potential exclusion criteria not mentioned in the patient note.",
            "eligibility_score_E": 40.0
        },
        "NCT02467309": {
            "relevance_explanation": "The patient note describes a 44-year-old man with a skull fracture, clear fluid dripping from his nose, severe headache, and fever. However, the clinical trial is focused on Vitamin D levels in children with bacterial meningitis. The patient's condition does not match the target condition of the trial, which is specifically looking at bacterial meningitis in children. The patient's symptoms and condition do not align with the inclusion criteria for the trial, making the patient irrelevant to the clinical trial.",
            "relevance_score_R": 0.0,
            "eligibility_explanation": "The patient does not meet the inclusion criteria for the clinical trial because the patient's condition is not bacterial meningitis. The patient is also not a child, which is a key demographic for the trial. The patient note does not indicate any of the exclusion criteria such as congenital immunodeficiency, HIV, corticosteroid treatment for long time, disorders in adrenal gland and pituitary gland and hypothalamus, or tuberculosis. However, due to the patient not meeting the inclusion criteria and the trial's specific focus on children with bacterial meningitis, the patient is not eligible for the trial.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-201513": {
        "NCT01255670": {
            "relevance_explanation": "The patient note does not explicitly mention peritonsillar abscess, but symptoms like dysphagia and drooling could be related to an abscess. However, without direct evidence of peritonsillar abscess, this criterion is not directly applicable. The patient's age and symptoms suggest a potential relevance to the clinical trial, but the lack of explicit diagnosis of peritonsillar abscess reduces the relevance score.",
            "relevance_score_R": 20.0,
            "eligibility_explanation": "The patient is a 5-year-old boy and thus is not voluntary in the same sense as an adult patient would be. The patient note mentions that the patient will provide informed consent and comply with the trial protocol but given the patient's age this seems to refer to the parents or guardians. Several inclusion and exclusion criteria are not applicable due to the patient's age or lack of information. The patient is excluded due to the need for in-patient care as implied by the presentation to the emergency department.",
            "eligibility_score_E": -20.0
        }
    },
    "sigir-201514": {
        "NCT00827463": {
            "relevance_explanation": "The patient is a 27-year-old woman in her second pregnancy with a hemoglobin (Hb) level of 9.0 g/dL, indicating anemia. The clinical trial is focused on the early detection of anemia during pregnancy, which aligns with the patient's condition. The patient's iron deficiency anemia and ongoing iron supplementation further support the relevance of this trial to her situation. The repeated blood cell counts and additional tests such as the reticulocyte count and hematology consult also indicate that her anemia is being closely monitored and managed. Given that the trial aims to estimate the efficiency of premature screening of maternal anemia and the patient is already under care for anemia at an early stage of pregnancy (11 weeks gestation) and is receiving iron supplementation, she is a highly relevant candidate for this study.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being followed at the HME at the beginning of pregnancy. There is no clear evidence that she doesn't speak French or that she has beta thalassemia. Additionally, there is no mention of previous conceptional treatment against anemia. However, the patient does have iron deficiency anemia and is on iron supplementation. Considering the criteria provided and the information in the patient note, the patient seems to be eligible for the trial as there are no explicit exclusions mentioned that apply to her. The patient's difficulty swallowing and the presence of hemosiderin in the urine are notable but do not directly relate to the exclusion criteria provided. Thus, based on the given criteria and the patient's profile, she appears to be eligible.",
            "eligibility_score_E": 90.0
        },
        "NCT01308112": {
            "relevance_explanation": "The patient is a 27-year-old woman with a hemoglobin level of 9.0 g/dL, which is relevant to the clinical trial focused on prenatal iron and malaria. However, the patient's condition and the trial's target condition do not perfectly align as the trial specifically targets malaria in pregnant women and the patient's primary issue is iron deficiency anemia rather than malaria. Despite this, the patient's iron deficiency anemia could be indirectly related to the trial's purpose as iron deficiency is a common issue in pregnant women and can be exacerbated by malaria. Thus, while the patient is not perfectly relevant to the trial's primary objective, her condition does intersect with the broader context of prenatal health and iron supplementation which the trial aims to study.",
            "relevance_score_R": 40.0,
            "eligibility_explanation": "The patient is ineligible for the clinical trial based on the provided criterion-level eligibility predictions. Specifically, the patient does not meet inclusion criterion 1 because her gestational age is 11 weeks which is less than the required 23 weeks. Although she meets other inclusion criteria such as being within the age range of 15-45 years and providing a blood sample, and does not meet any of the exclusion criteria listed, the failure to meet this one critical inclusion criterion disqualifies her from participating in the trial.",
            "eligibility_score_E": -40.0
        }
    },
    "sigir-201515": {
        "NCT00932425": {
            "relevance_explanation": "The patient, Karen\u201a is a 72-year-old woman with hypertension and type 2 diabetes who was hospitalized for cryptogenic stroke two weeks ago. This condition is explicitly mentioned in the trial criteria as the trial focuses on long-term cardiac monitoring after cryptogenic stroke. Therefore\u201a the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria: she is above 18 years old\u201a was seen at a medical center for cryptogenic stroke\u201a and had onset of stroke symptoms within the previous 60 days. Additionally\u201a she does not have any of the exclusion criteria such as definite small-vessel etiology\u201a source found on vascular imaging of possible culprit vessels\u201a history of atrial fibrillation\u201a atrial fibrillation on admission ECG\u201a or obvious culpable systemic illness. The patient is also able to provide informed consent and will comply with the trial protocol. Therefore\u201a the patient is fully eligible for the clinical trial.",
            "eligibility_score_E": 90.0
        },
        "NCT01550588": {
            "relevance_explanation": "The patient had a cryptogenic stroke within the previous 3 months, which is a key inclusion criterion for the clinical trial. The trial focuses on patients with cryptogenic stroke and high-risk patent foramen ovale (PFO), and the patient's condition aligns with this focus. However, the patient's PFO size and other specifics are not detailed in the note, which could affect the relevance score. Given the information, the patient is relevant to the trial because of the cryptogenic stroke but lacks detailed information on the PFO size and other risk factors.",
            "relevance_score_R": 60.0,
            "eligibility_explanation": "The patient meets some inclusion criteria such as having a cryptogenic stroke within the previous 3 months and being willing to participate in follow-up visits. However, the patient does not meet the criterion of being diagnosed with a high-risk PFO as the echocardiographic verification of PFO size or presence of atrial septal aneurysm is not mentioned. The patient also reports symptoms like palpitations, shortness of breath, and chest pain but these are not explicitly linked to the PFO or cryptogenic stroke in a way that clearly meets or excludes the patient from the trial based on provided information. The absence of clear evidence for high-risk PFO and some symptoms that could be related to other conditions makes the patient's eligibility uncertain based on the given note.",
            "eligibility_score_E": 0.0
        }
    },
    "sigir-201516": {
        "NCT00839124": {
            "relevance_explanation": "The patient presents with wheezing, which is a symptom relevant to the clinical trial focused on asthma and hypersensitivity. The patient's history of allergic rhinitis and the recent onset of wheezing after playing in the backyard sandbox suggest a potential allergic or asthmatic reaction. These factors make the patient relevant to the trial. However, the patient's condition and symptoms need to be further evaluated against the trial's specific inclusion and exclusion criteria to determine eligibility.",
            "relevance_score_R": 70.0,
            "eligibility_explanation": "The patient's eligibility is uncertain due to limited information about lung function, oxygen saturation, and blood pressure. The patient meets some criteria such as having a history consistent with asthma (episodic wheezing) but does not meet others due to lack of information. The patient is excluded by criterion 8 (nighttime symptoms of cough or wheeze greater than 1x/week at baseline) as the patient has been audibly wheezing since the incident. Other exclusion criteria such as chronic medical conditions or recent use of systemic steroids do not apply based on the provided information.",
            "eligibility_score_E": -30.0
        },
        "NCT00930826": {
            "relevance_explanation": "The patient presents with wheezing and has a history of allergic rhinitis, which is relevant to the clinical trial focused on childhood asthma. The symptoms of wheezing and coughing, as described in the patient note, align with the target condition of bronchial asthma. Therefore, the patient is relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of having a clinical diagnosis of bronchial asthma as indicated by wheezing and coughing symptoms. There is no mention of the patient being unable to swallow tablets or having a history of steroid inhalation or ingestion that would exclude them from the trial. However, the patient's ability to swallow tablets is not directly confirmed in the patient note. Given the information provided and the criteria outlined, the patient appears to be eligible for the trial based on the available information.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-201517": {
        "NCT01446198": {
            "relevance_explanation": "The patient is relevant to the clinical trial because she has a valid positive HPV result from her recent PAP smear, which aligns with the target condition of the trial (Human Papilloma Virus Infection). Although the patient note does not directly mention the APTIMA HPV Assay TIGRIS System result, the positive HPV result implies relevance to the trial\u2019s objective of evaluating the APTIMA HPV Assay performance. The patient\u2019s good health and willingness to comply with the trial protocol further support her relevance.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is likely eligible for the clinical trial because she meets some of the inclusion criteria. She has a valid positive HPV result and is willing to provide informed consent and comply with the trial protocol. However, there is not enough information to confirm whether she meets all the inclusion criteria (e.g., having an aliquot with a valid positive or negative APTIMA HPV Assay TIGRIS System result) or whether an aliquot is available and suitable for testing. Additionally, the patient note does not mention the sample being randomly selected for inclusion. Despite these uncertainties, the patient is not excluded by any of the exclusion criteria mentioned (sample integrity was not compromised). Therefore, while there are some uncertainties, the available information suggests the patient could be eligible.",
            "eligibility_score_E": 60.0
        },
        "NCT01231945": {
            "relevance_explanation": "The patient is a 32-year-old female with no previous medical history, presenting for a discussion about her recent Pap smear results. The clinical trial focuses on low-cost molecular cervical cancer screening, which includes HPV testing. Given that the patient's Pap result was cytology negative but HPV positive, this trial is highly relevant to her situation as it aims to evaluate the clinical performance of low-cost molecular tests for HPV in detecting cervical cancer and precancerous lesions.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for the clinical trial: she is a woman between 25 and 65 years of age (32 years old) and has not been previously diagnosed with cervical cancer. She also has a cervix and is not pregnant. Additionally, she is physically able to undergo routine cervical cancer screening and able to provide informed consent. There is no mention of her being married or having had sexual intercourse in the context of exclusion criteria; however, this does not affect her eligibility based on the provided information. The patient does not have a history of cervical cancer and is not physically or mentally unable to undergo the screening or provide informed consent. Since there is no indication that she is currently menstruating at the time of enrollment or has been pregnant in the last month, these exclusion criteria do not apply to her.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201518": {
        "NCT00344513": {
            "relevance_explanation": "The patient's symptoms, such as shortness of breath related to exertion and difficulty breathing when lying flat, are consistent with heart failure. The patient's physical exam findings, including bibasilar lung crackles, pitting ankle edema, and jugular venous distension, further support the relevance of this trial to the patient's condition. The clinical trial's focus on heart failure and its symptoms aligns with the patient's presentation, making this trial highly relevant.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion 0 for being hospitalized for an episode of worsening heart failure as the primary cause of admission. However, the patient is not included based on criterion 1 due to systolic dysfunction (LVEF < 40%) or heart failure symptoms in the setting of preserved systolic function (diastolic dysfunction). Since there are no exclusion criteria mentioned, the patient is not excluded based on criterion 0. The patient's ability to provide informed consent and comply with the trial protocol is also a positive factor. Nevertheless, the patient's eligibility is impacted by not meeting one of the inclusion criteria, thus the eligibility score is not at its maximum potential.",
            "eligibility_score_E": 40.0
        },
        "NCT00534066": {
            "relevance_explanation": "The patient's symptoms, such as shortness of breath related to exertion and difficulty breathing when lying flat, are directly related to congestive heart failure (CHF), which is the primary condition being studied in the clinical trial. The patient's physical exam findings, including bibasilar lung crackles, pitting ankle edema, and jugular venous distension, further support the relevance of this patient to the trial. The patient's age and ability to provide informed consent also align with the trial's criteria.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for age (65 years old) and has a primary diagnosis of CHF, as indicated by symptoms and physical exam findings. Although the patient note does not explicitly state admission to the hospital or transfer to the Observation Unit, the severity of symptoms suggests that hospital admission or observation would be necessary. The patient is not excluded by any of the exclusion criteria (minors, prisoners, pregnant women, unable to provide consent, unstable angina or acute myocardial infarction in the ED, dialysis dependent patients, or use of nesiritide as a therapy in the ED). Therefore, the patient is considered eligible for the trial.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201519": {
        "NCT00806091": {
            "relevance_explanation": "The patient has a significant smoking history and chronic cough, which are directly related to the clinical trial's target condition of COPD. The patient's symptoms such as progressive shortness of breath and moderate respiratory distress also align with the trial's focus on the functional proteomics of alveolar macrophages in the context of COPD. Therefore, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criterion of being a COPD smoker as evidenced by their significant smoking history and chronic cough. The patient's willingness to provide informed consent and comply with the trial protocol also supports their eligibility. Although the patient's smoking status is well-documented, there is no direct information that would exclude them based on the provided criteria. Hence, the patient is considered eligible for the trial.",
            "eligibility_score_E": 90.0
        },
        "NCT02213809": {
            "relevance_explanation": "The patient note describes a 66-year-old female with a significant smoking history and chronic cough, which are symptoms commonly associated with Chronic Obstructive Pulmonary Disease (COPD). The clinical trial focuses on COPD education for general practitioners. Given the patient's symptoms and history, she is relevant to the clinical trial as her condition aligns with the target condition of the trial (COPD). The trial aims to educate general practitioners on diagnosing and treating COPD through case method education or traditional education. Since the patient has COPD symptoms and a long history of smoking (1 to 2 packs per day for 47 years), her participation could contribute valuable insights into the effectiveness of the educational methods for managing COPD.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient is eligible based on the provided information. She has a diagnosis that can be associated with COPD (chronic cough and progressive shortness of breath) and has a significant smoking history. The criterion-level eligibility predictions indicate that she meets the inclusion criterion related to the diagnosis of COPD. Although specific details about her COPD grade or spirometry results since 2008 are not provided in the patient note, the information given suggests she could be at a stage relevant to the trial (Grade 2-3). There are no explicit exclusion criteria mentioned in the patient note that would disqualify her from participating in the trial.",
            "eligibility_score_E": 80.0
        }
    },
    "sigir-201520": {
        "NCT00880347": {
            "relevance_explanation": "The patient's condition, as described in the patient note, aligns with the clinical trial's target conditions of Alzheimer's Disease and Dementia. The patient exhibits progressive changes in cognition and personality over six months\u201a including poor memory\u201a difficulty expressing himself\u201a and unusual behaviors. These symptoms are relevant to the clinical trial's objective of defining the performance of blood-based signatures for Alzheimer's Disease in different patient populations. Therefore\u201a the patient is relevant to the clinical trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets some inclusion criteria such as being aged \u2265 40 years old and having a clinical diagnosis of probable AD. However\u201a the patient is excluded by several exclusion criteria\u201a including the presence of significant paratonic rigidity and myoclonic jerks which may be related to another type of dementia. Additionally\u201a there is no direct evidence of brain imaging results compatible with AD diagnosis. The patient's eligibility is also affected by the absence of certain information\u201a such as the presence of other signs or symptoms that may be better related to another type of dementia. Despite this\u201a the patient is compliant with study procedures and will provide informed consent. Considering these factors\u201a the patient's eligibility score is negatively impacted.",
            "eligibility_score_E": -30.0
        },
        "NCT00182832": {
            "relevance_explanation": "The patient's condition, which includes progressive changes in cognition and personality, poor memory, difficulty expressing himself, and unusual behaviors, aligns with the target conditions of the clinical trial (Cognitive Impairment and Delirium). The patient's age (89 years old) and hospitalization in a medical ward also match the trial's inclusion criteria. Therefore, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 95.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of being 65 years or older (89 years old), being hospitalized in a medical ward (brought to the emergency department), and having cognitive impairment (exhibited by poor memory, difficulty expressing himself, and unusual behaviors). Although there is no direct information about the patient's ability to speak English, the fact that the patient note is written in English and the patient is described as able to express himself suggests that the patient can speak English. The patient is not excluded by any of the exclusion criteria (not previously enrolled in the study during prior hospitalization, not enrolled in another clinical trial, and does have cognitive impairment based on screening at the time of hospital admission). Therefore, the patient is eligible for the clinical trial.",
            "eligibility_score_E": 95.0
        }
    },
    "sigir-201521": {
        "NCT02105714": {
            "relevance_explanation": "The patient presents with symptoms of diarrhea, abdominal cramping and flatulence which aligns with the clinical trial's focus on persistent digestive disorders. The patient's recent hiking trip and consumption of water from natural sources could be a risk factor for contracting a neglected tropical disease (NTD) as targeted by the trial. The presence of ellipsoidal cysts in the stool smear further supports the relevance of this trial to the patient's condition.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for age and symptoms (persistent diarrhea) and has provided informed consent. There is no indication that the patient requires immediate intensive or surgical care, is unable to comply with the study requirements, or is participating in other diagnostic studies or clinical trials. The patient's condition does not show clinical jaundice. Thus, the patient is eligible for the trial based on the provided information.",
            "eligibility_score_E": 90.0
        },
        "NCT01959048": {
            "relevance_explanation": "The patient presents with symptoms such as diarrhea, abdominal cramping and flatulence which are indicative of Clostridium difficile associated disease (CDAD). The patient also has a confirmed diagnosis of an ellipsoidal cyst which could be related to CDAD. The clinical trial is focused on the efficacy and safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis. Given the patient's symptoms and diagnosis, the trial is highly relevant to the patient's condition.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria for the clinical trial: both genders are eligible (patient is male), age 18 years and older (patient is 32 years old), able to provide written informed consent (patient will provide informed consent and comply with the trial protocol), and has a confirmed diagnosis of severe CDAD. The patient does not have any of the exclusion criteria: not pregnant or lactating (patient is male), no need for prolonged antibiotics for other causes (diarrhea attributed to Clostridium difficile), no other known etiology for diarrhea or clinical infection with other known enteric pathogens (condition directly related to CDAD), no active or chronic conditions such as Inflammatory bowel disease or Ulcerative colitis (no mention of such conditions), no laxatives or motility-altering drugs within 12 hours of enrolment (no mention), not clinically unstable (no mention of hypotension or hemodynamic instability), no condition that would preclude safe participation in the trial (no indication of any precluding condition), no immune suppression or HIV (no indication), and no prior colon surgery (no mention). Therefore, the patient is fully eligible for the clinical trial.",
            "eligibility_score_E": 90.0
        }
    },
    "sigir-201522": {
        "NCT02534727": {
            "relevance_explanation": "The patient has a history of tuberculosis, which is one of the target conditions for the clinical trial. The patient's symptoms such as productive cough with tinges of blood and the presence of a round opaque mass within a cavity in his left upper lobe as revealed by Chest X-ray are consistent with the clinical presentation of tuberculosis. Furthermore, the culture of the sputum showing an organism with septated low-angle branching hyphae is indicative of Mycobacterium infection. Therefore, the patient is highly relevant to the clinical trial.",
            "relevance_score_R": 95.0,
            "eligibility_explanation": "The patient meets several inclusion criteria for the clinical trial: the patient is at least 18 years of age, has a diagnosis of TB, has ongoing signs and/or symptoms of pulmonary TB, and is suspected to have drug-resistant TB. Additionally, the patient is available to provide at least 3 sputum samples over 2 or more days and is taking anti-tuberculosis medicines during the time sputum are provided. The patient is also thought likely to be Mycobacterium culture positive by the enrolling physician and is likely able to produce sputum samples while on study. The patient is willing to provide blood samples and have samples stored. There is no direct evidence of acute liver or kidney disease or conditions that compromise the subject's ability to take or absorb oral drugs. Therefore, the patient is eligible for the clinical trial.",
            "eligibility_score_E": 95.0
        },
        "NCT01207128": {
            "relevance_explanation": "The patient note describes a condition that does not match the target condition of the clinical trial, which is invasive aspergillosis. The patient has a history of tuberculosis and complains of productive cough with tinges of blood. The clinical trial is focused on evaluating the therapeutic effectiveness of combination antifungal therapy for invasive aspergillosis. Given the mismatch between the patient's condition and the trial's target condition, the patient is not relevant to the clinical trial.",
            "relevance_score_R": 0.0,
            "eligibility_explanation": "The patient does not meet the inclusion criterion of having a diagnosis of proven or probable invasive aspergillosis. Although the patient is 65 years old and thus meets the age criterion and provides informed consent as required by the trial protocol and is not being treated with an unlicensed investigational drug for aspergillosis and meets other criteria such as not being pregnant or lactating and not having hepatic cirrhosis or a history of allergy to the azole or echinocandin class of antifungal agents and not previously enrolled into this study and not having an active microbiologically-documented deep infection due to a non-Aspergillus mold. However the patient is excluded due to not meeting the primary diagnosis criterion for invasive aspergillosis and due to having a concomitant medical condition which in this case is the history of tuberculosis that may create an unacceptable additional risk.",
            "eligibility_score_E": -0.0
        }
    },
    "sigir-201523": {
        "NCT00084240": {
            "relevance_explanation": "The patient is an 18-year-old male presenting with symptoms such as high fever, chills, facial flushing, epistaxis and severe headache and joint pain after returning from a recent vacation in Asia. These symptoms align with the clinical trial's target condition of uncomplicated symptomatic falciparum malaria in Southeast Asia. The patient's age and symptoms make this trial relevant to the patient's condition.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the age criterion for the trial and has symptoms consistent with uncomplicated symptomatic malaria. However, the patient is excluded due to having leukopenia and thrombocytopenia as reported in the complete blood count, which falls under the exclusion criterion of known history of blood dyscrasias. Despite meeting some inclusion criteria and not being excluded by most other criteria, the patient's eligibility is negatively impacted by this specific exclusion.",
            "eligibility_score_E": -45.0
        },
        "NCT02334514": {
            "relevance_explanation": "The patient presents with symptoms that suggest influenza virus infection, including high fever, headache and joint pain. These symptoms align with the clinical presentation that suggests influenza virus infection as specified in the trial's inclusion criterion 0. Although the patient's note does not provide direct evidence of a positive PCR test for influenza virus (inclusion criterion 1) or mention anti-viral treatment being indicated (inclusion criterion 2), the symptoms described are consistent with the target condition of the clinical trial. Therefore, the patient is considered relevant to the clinical trial.",
            "relevance_score_R": 80.0,
            "eligibility_explanation": "The patient meets one of the inclusion criteria (clinical presentation suggesting influenza virus infection). However, there is no direct evidence in the patient's note of a positive PCR test for influenza virus (inclusion criterion 1), which is required for eligibility. Additionally, the note does not mention anti-viral treatment being indicated (inclusion criterion 2). The patient does not meet any of the exclusion criteria mentioned (immune-compromised patients, pregnant women, or previous treatment with oseltamivir in the last 6 months). Given the information provided, the patient is not fully eligible due to lacking confirmation of influenza virus infection by PCR test and no indication of anti-viral treatment. However, since the patient presents with relevant symptoms and does not meet any exclusion criteria, a moderate eligibility score is assigned.",
            "eligibility_score_E": 40.0
        }
    },
    "sigir-201524": {
        "NCT00711399": {
            "relevance_explanation": "The patient presents with productive cough and chest pain, which are symptoms relevant to the clinical trial's target conditions of respiratory sounds. The patient's condition of having a productive cough and shortness of breath aligns with the trial's inclusion criteria. Furthermore, the patient's willingness to provide informed consent and comply with the trial protocol as mentioned in sentence <6.> also supports the relevance of this patient to the trial.",
            "relevance_score_R": 90.0,
            "eligibility_explanation": "The patient meets the inclusion criteria of having cough or shortness of breath and has signed informed consent. However, the patient is excluded due to respiratory distress as evidenced by expiratory wheezing, decreased breath sounds, and egophany in the left lower lung field. Despite meeting some criteria, the presence of an exclusion criterion affects the patient's eligibility.",
            "eligibility_score_E": -45.0
        }
    }
}